166 filings
Page 2 of 9
6-K
ynis44j1j85n5z4uzhfz
9 May 23
Current report (foreign)
7:14am
6-K
x6udtm2
4 May 23
Current report (foreign)
4:15pm
6-K
qwfmc ctois
4 May 23
Galmed Pharmaceuticals forms a Strategic Partnership
4:14pm
6-K
vfbpiwk1q1us7h8v8s
30 Mar 23
Current report (foreign)
4:27pm
6-K
ugm5056s
8 Feb 23
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
8:15am
6-K
c2b3ez78
5 Jan 23
Current report (foreign)
4:30pm
6-K
m58n8oplww5o
4 Jan 23
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
8:11am
6-K
q6i snoqrci52of6h8
14 Dec 22
Current report (foreign)
5:08pm
6-K
pkbi2 yju
16 Nov 22
Current report (foreign)
5:00pm
6-K
r4m1 mcn36u8sm
4 Aug 22
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
8:00am
6-K
6vb vw2v8
7 Jul 22
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
8:47am
6-K
xh0bwn8io5742bilb
29 Jun 22
Current report (foreign)
4:30pm
6-K
bhl5g1
22 Jun 22
Current report (foreign)
5:00pm
6-K
9gj00xy
17 Jun 22
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
4:15pm
6-K
ftwya1w pvr7cb
17 May 22
Current report (foreign)
9:08am
6-K
oujen818 hxk8
17 May 22
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
8:20am
6-K
0puh1787c8knjzm
17 May 22
Galmed updates business and clinical development strategy to better leverage Aramchol’s anti-fibrotic effects
7:51am
6-K
qxin r4zwv
2 May 22
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial
7:07am
6-K
1ct38t lza
28 Apr 22
Current report (foreign)
8:04am
6-K
exkulllzuoe
3 Mar 22
Current report (foreign)
5:16pm